Zentalis price target raised to $10 from $9 at Stifel

Stifel analyst Bradley Canino raised the firm’s price target on Zentalis to $10 from $9 and keeps a Buy rating on the shares. The formal discontinuation of the ZN-d5+azenosertib program in Acute Myeloid Leukemia will unlikely be a surprise, as focus needs to be on azenosertib in platinum-resistant ovarian cancer after the partial clinical hold, the analyst tells investors in a research note. The firm says the thesis is challenging until the data are public and the FDA partial clinical hold is resolved.